Dr. Jaya Juturi, MD
What this data tells you about Dr. Juturi
Dr. Jaya Juturi is a hematology & oncology in Dallas, TX, with 20 years in practice. Based on federal Medicare data, Dr. Juturi performed 80,536 Medicare services across 4,230 unique beneficiaries.
Between the years covered by Open Payments, Dr. Juturi received a total of $2,582 from 22 pharmaceutical and/or device companies across 39 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Juturi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 14,800 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 13,650 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 12,090 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 10,100 | $42 | $137 |
| Oxaliplatin chemotherapy injection | 6,700 | $0 | $33 |
| Paclitaxel chemotherapy injection | 6,018 | $0 | $8 |
| Dexamethasone injection (steroid) | 1,627 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,370 | $21 | $181 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,230 | $1 | $114 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,130 | $24 | $155 |
| Blood draw (venipuncture) | 1,121 | $8 | $20 |
| Immune globulin infusion (Octagam) | 1,070 | $33 | $233 |
| Complete blood count (CBC) with differential | 1,043 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,002 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 950 | $0 | $24 |
| Injection, atropine sulfate, 0.01 mg | 840 | $0 | $1 |
| Office visit, established patient (30-39 min) | 440 | $87 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 368 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 313 | $102 | $707 |
| Injection, irinotecan, 20 mg | 301 | $2 | $210 |
| Injection, fluorouracil, 500 mg | 293 | $2 | $13 |
| Injection, carboplatin, 50 mg | 277 | $2 | $300 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 264 | $82 | $1,348 |
| Office visit, established patient, complex (40-54 min) | 243 | $137 | $496 |
| Injection, zoledronic acid, 1 mg | 216 | $6 | $431 |
| Immunoglobulin level test | 171 | $9 | $56 |
| Injection of additional new drug or substance into vein | 148 | $12 | $108 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 146 | $50 | $313 |
| Injection, potassium chloride, per 2 meq | 145 | $0 | $1 |
| Ferritin level test (iron stores) | 134 | $13 | $60 |
| Iron level test | 134 | $6 | $27 |
| Iron binding capacity test | 134 | $9 | $35 |
| Drug injection, under skin or into muscle | 132 | $11 | $96 |
| Infusion, normal saline solution , 1000 cc | 132 | $2 | $19 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 130 | $3 | $373 |
| Injection, diphenhydramine hcl, up to 50 mg | 113 | $1 | $7 |
| Administration of chemotherapy into vein, each additional hour | 109 | $23 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 95 | $52 | $344 |
| Measurement of immunoglobulin light chains | 90 | $17 | $60 |
| Injection, magnesium sulfate, per 500 mg | 90 | $1 | $6 |
| Lactate dehydrogenase (enzyme) level | 89 | $6 | $31 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 88 | $71 | $70 |
| Carcinoembryonic antigen (cea) protein level | 82 | $19 | $99 |
| New patient office visit, complex (60-74 min) | 81 | $164 | $709 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 80 | $20 | $128 |
| Unclassified drugs | 64 | $1 | $8 |
| Microscopic examination for white blood cells with manual cell count | 55 | $4 | $22 |
| Complete blood count (CBC), automated | 54 | $6 | $34 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 53 | $58 | $211 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 51 | $1 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 48 | $16 | $100 |
| Infusion into a vein for hydration, 31-60 minutes | 46 | $26 | $256 |
| Office visit, established patient (20-29 min) | 43 | $56 | $250 |
| Infusion into a vein for hydration, each additional hour | 42 | $10 | $75 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 38 | $135 | $3,675 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $27 | $145 |
| Hospital follow-up visit, high complexity | 31 | $94 | $357 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 31 | $135 | $500 |
| Initial hospital admission, high complexity | 27 | $136 | $694 |
| Injection, lorazepam, 2 mg | 25 | $1 | $3 |
| Application of on-body injector for under skin injection | 21 | $15 | $96 |
| Echocardiogram, transthoracic | 20 | $110 | $805 |
| New patient office visit (45-59 min) | 20 | $121 | $565 |
| Hospital follow-up visit, moderate complexity | 20 | $62 | $247 |
| Injection of drug or substance into vein | 18 | $30 | $247 |
| Red blood count automated, with additional calculations | 13 | $5 | $26 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (35%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Juturi is a mixed practice specialist, with above-average Medicare volume (top 11% in TX), and mixed engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Juturi experienced with iron sucrose injection (venofer)?
Does Dr. Juturi receive payments from pharmaceutical companies?
How do Dr. Juturi's costs compare to other hematology & oncologys in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology